G PROTEIN-COUPLED RECEPTOR INHIBITOR AND PHARMACEUTICAL PRODUCT
申请人:Tsujimoto Gozo
公开号:US20100274022A1
公开(公告)日:2010-10-28
Disclosed are a substance and a pharmaceutical product inhibiting activation of a G protein-coupled receptor. Specifically disclosed is a G protein-coupled receptor inhibitor containing a specific compound represented by the following formula (1):
To develop novel PPAR alpha ligands, we designed and synthesized several 3-3-[2-(nonylpyridin-2-ylamino)ethoxy]phenyl}-propanoic acid derivatives. Compound 10, the meta isomer of a PPAR gamma agonist 1, has been identified as a PPAR alpha ligand. The introduction of methyl and ethyl groups at the C-2 position of the propanoic acid of 10 further improved the PPAR alpha-binding potency. (c) 2006 Elsevier Ltd. All rights reserved.
EP2154131
申请人:——
公开号:——
公开(公告)日:——
Design, synthesis, and biological activity of novel PPARγ ligands based on rosiglitazone and 15d-PGJ2
To develop novel PPAR gamma ligands, we synthesized thirteen 3-4-(2-aminoethoxy)phenyl}propanoic acid derivatives, which are designed based on the structures of rosiglitazone and 15d-PGJ(2). Among these compounds, compound 9 was found to be as potent as rosiglitazone in a binding assay and a preadipocyte differentiation test. Molecular modeling suggested that the nonyl group of 9 interacted with hydrophobic amino acid residues constructing the hydrophobic region of PPAR gamma protein where the alkyl chain of 15d-PGJ(2) is expected to be located. (c) 2005 Elsevier Ltd. All rights reserved.
Synthesis and Evaluation of 2-Nonylaminopyridine Derivatives as PPAR Ligands
To find novel PPAR ligands, we prepared several 3-3 or 4-[2-(nonylpyridin-2-ylamino)ethoxy]phenyl}propanoicacidderivatives which were designed based on the structure of our previous PPARgamma ligand 1. In PPAR binding affinity assays, compound 4, which had an ethoxy group at the C-2 position of the propanoicacid of 1, showed selective binding affinity for PPARgamma. Compound 3, with an ethyl group